



## Drug Shortage – bupivacaine/epinephrine injection

- The [drug shortage](#) of [bupivacaine/epinephrine](#) injection products is ongoing. These products have been unavailable for at least 90 days.
  - Fresenius Kabi's bupivacaine/epinephrine injection products are in shortage due to increased demand. These products are backordered, and estimated availability is late March 2021.
  - Hospira's bupivacaine/epinephrine injection products are in shortage due to manufacturing delays. Estimated availability is June 2021.
  - Fresenius Kabi and Hospira are the only manufacturers of bupivacaine/epinephrine injection products.
  - The complete list of bupivacaine/epinephrine injection product descriptions and NDC numbers are available in the drug shortage link [here](#).
- Bupivacaine/epinephrine injection products are indicated for the production of local or regional anesthesia or analgesia for surgery, dental and oral surgery procedures, diagnostic and therapeutic procedures and for obstetrical procedures.
- Bupivacaine/epinephrine injection is administered prior to various surgical or diagnostic procedures. We did not identify any member utilization for these products in OptumRx pharmacy claims data for the past 120 days.



OptumRx<sup>®</sup> specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum<sup>®</sup> company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum<sup>®</sup> trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews<sup>®</sup> is published by the OptumRx Clinical Services Department.

©2021 Optum, Inc. All rights reserved.